Abstract
Introduction
Cardiovascular disease, especially Coronary Heart disease (CHD) is the number one killer and foremost cause of deaths around the world [1] . Angina pectoris, the prime symptom of coronary heart disease ranked first among causes of mortality [2] . The current non-pharmacological and non-invasive therapy available EECP effect on quality of life (n = 7)
Full-text articles assessed for eligibility (n = 102)
Full text articles excluded (n = 42) Included Eligibility for chronic stable angina (a typical symptom of coronary heart disease) and heart failure is Enhanced External Counter Pulsation (EECP). EECP is USA-FDA approved therapy for coronary heart disease patient [3] . EECP, an electro-mechanical system is a registered trademark of Vasomedical, Inc, New York, USA and PSK (Chinese Company) is the exclusive distributor of Vasomedical'sdevices all over the world [4] [5] [6] [7] [8] . CHD patients usually undergo EECP treatment of 35 consecutive 1-hour sessions over 5-7 weeks. Treatment patient is continuously monitored for cardiac outputs, heart rate and spo2 using ECG and finger plethysmogram, which are connected to the EECP device [9] [10] [11] . This study designed to evaluate the effect of EECP in Clinical profile and HRQoL in CHD patients.
Material and methods searching methods
A systemic review of the literature of EECP on clinical profile and HRQoL in coronary heart disease patients was search through PubMed, Medline, Vasomedical EECP manufacturer web-link, and Google scholar sources. Searching for the articles done as per the inclusion and exclusion criteria of the study and the studies summarized in Figure 1 .
Inclusion criteria
EECP article of Randomized Control Trial (RCT), case studies, prospective and retrospective studies on clinical profile and HRQoL in coronary heart disease patients were included.
Exclusion criteria
Heart Failure studies, Non-cardiac EECP studies with RCT, Case studies, Prospective and Retrospective and reviews of EECP papers excluded from the study.
Quality assessment
Study quality was assessed through two authors independently. Newcastle-Ottawa scale (NOS) was used to assess the quality of studies. Detail of assessment is given in Tables 1, 2 . 
EFFECT OF EECP ON CLINICAL PROFILE IN CORONARY HEART DIsEAsE PATIENTs
Lawson et al. [12] conducted a study on 18 patients with chronic angina treated with an improved system of enhanced external counter pulsation (EECP) and found that all patients improved in angina symptoms and generally decreased anti-angina medications. A decrease in myocardial ischemia observed in 67% patients and 89% of patients were symptom-free. Sjukri et al. [13] carried out a study on 201 coronary heart disease patients. The results of the study showed significant improvement in coronary perfusion by 86.8% and exercise tolerance by 94.2%. Arora et al. [14] performed a multi centric prospective randomized control study to assess the safety and efficacy of enhanced external counterpulsation (EECP). A significant improvement in angina severity and exercise tolerance and timing was reported. EECP showed well tolerated and safe therapy for CHD patients. Lawson et al. [15] carried out a study on 33 patients to evaluate the effect of EECP on longterm prognosis in CHD patients. The study suggests that particularly for the majority of patients demonstrating improvement by 64% in radionuclide stress perfusion post-treatment and EECP may be an effective long-term therapy. Lawson et al. [16] conducted a cohort study in 2,289 CHD patients to evaluate EECP safety and efficacy. EECP was found to be safe and well-tolerated therapy with improvement in angina class by 74% with significant p-value (p < 0.001). Urano et al. [17] performed a study on 512 CHD patients to examined EECP efficacy in myocardial ischemia, exercise tolerance and cardiac [20] conducted a study on 28 CHD patients to assess psychological function and well-being status and observed significant improvement in psychological and well-being status. Lakshmi et al. [21] carried out a study on 2486 patients those were enrolled in the IEPR. The study revealed a significant improvement in angina class in patients whose DA ratio was increased and results sustained for 6 months. Stys et al. [22] performed a study on 175 CHD patients and found a significant improvement in angina class in 85% of patients. This study results showed the EECP effectiveness in improving stress myocardial perfusion with exercise tolerance in CAD patients. Michaels et al. [23] conducted a study on 10 CHD patients and found the significant improvement in diastolic and mean pressures with reduction of systolic pressure in the central aorta and the coronary artery of CAD patients. The study concludes that EECP may serve as a potential mechanical assistant device for CAD patients. holubkov et al. [24] carried out a study on 771 CHD patients treated with EECP and the results of this study conclude that EECP may be a safe treatment option for CAD patients. Soran et al. [25] performed a study on 1402 CHD patients and the results showed that angina decreased by at least one class in 67% of patients with LV dysfunction just after completion of EECP treatment.
Fitzgerald et al. [26] conducted a cohort study on 4669 CHD patients and found decreased angina episodes and nitroglycerin use and 74.8% reduction in Canadian Cardiovascular Society (CCS) functional class and improvement in angina sustained for 6 months. Bonetti et al. [27] performed a study on 23 CHD patients to examine the effect of enhanced external counter pulsation (EECP) on endothelial function and found that 70% patients get symptomatic relief by EECP treatment. The author revealed that significant improvement in endothelial function by EECP may benefit to the clinical status of CHD patients. schecter et al. [28] carried out a study of 20 CHD patients to investigate the influence of short-term external counterpulsation (ECP) therapy on flow-mediated dilation (FMD) in patients with coronary artery disease (CAD). The author revealed that external counter pulsation may improve vascular endothelial function and refractory angina pectoris in CHD patients. Tartaglia et al. [29] conducted a study on 25 CHD patients to determine the effect of EECP on exercise capacity and myocardial perfusion by comparing results of maximal exercise radionuclide testing pre-and post-EECP treatment. A significant improvement in treadmill times has been reported and radionuclide perfusion scores also showed a significant reduction in ischemic segments.
Werner et al. [30] performed a study on 48 CHD patients and weekly angina episodes were reduced by 48%, nitroglycerin puffs were reduced by 51%, work capacity was improved by 22%. Study validates the reduction of angina with significant improvement of work capacity after EECP.
Lawson et al. [31] carried out a study on 4592 CHD patients and his collected data from international enhanced external counter pulsation (EECP) patient regis- [32] conducted a study on 3037 CHD patients to determine whether enhanced external counterpulsation is a safe and effective treatment for angina in octogenarians. At 6-month follow-up, 81% of patients sustained angina improvement. This study concludes that enhanced external counterpulsation is effective and well tolerable non-invasive treatment.
Linnemeier et al. [33] performed another study on 1532 IEPR patients. The author demonstrated that after 1 year, maintenance of angina rate was reduced in 86% of patients with diabetes. This study also suggests that in diabetes patients, EECP can be a safe, effective, well-tolerated treatment option for the relief of angina.
Bagger et al. [34] carried out a study on 23 patients with angina pectoris with positive dobutamine stress echocardiogram. This study was done to evaluate EECP effectiveness on dobutamine stress-induced wall motion score among angina patients. The reduction in dobutamine-induced wall motion abnormalities after EECP therapy was reported. Michaels et al. [35] conducted the long-term outcomes of enhanced external counterpulsation in 1097 CHD patients to relieve angina and improving the quality of life in a large cohort of patients with chronic angina pectoris. 73% patients had a reduction by at least 1 angina class at the end of treatment, and 50% reported an improvement in the quality-of-life assessment after enhanced external counterpulsation was; these results were sustained at 2-year follow-up. Lawson et al. [36] performed a study on 2861 CHD patients to examine the safety and effectiveness of EECP therapy. Post-EECP, patients had improved their CCS angina by at least one class. At 6-month follow-up, the CCS-class improved reduction in angina episodes and nitroglycerin use. Enhanced external counterpulsation was proved an effective therapy in relieving angina in patient's angina patients. Masuda et al. [37] carried out a study on total 18 CHD patients. Out of 18 patients, 11 were treated with EECP and 7 were treated 5000 IU heparin pretreatment along with EECP. The study was done to evaluate EECP and intravenous heparin injection therapy effectiveness in angina pectoris patients and the results of the study showed significant improvement in exercise capacity and oxygen metabolism of coronary heart disease patients treated with combination therapy of EECP and heparin.
Henrikson et al. [38] conducted a study on 28 CHD patients and found that post EECP most patients (82%) had at least one full class improvement in their angina pattern. EECP remains an effective treatment for severe CAD. Taguchi et al. [39] performed study on 24 patients with myocardial infarction. This study was done to assess the haemodynamic effects of EECP and its mechanism with special reference to neurohumoral factors. The finding of this study suggests that an increase in ANP without an increase in BNP is an important mechanism for the effects of EECP therapy. Lawson et al. [40] carried out a study on 2007 CHD patients and demonstrated the angina reduction by 83% at least one CCS angina class and improvement in weekly angina episodes and their frequency of nitroglycerine use decreased with improvement in well-being status by 63%. Michaels et al. [41] conducted a study on 1192 CHD patients to assess the frequency, efficacy, predictors, and long-term success of repeat enhanced external counter pulsation (EECP) therapy in relieving angina in a large cohort of angina patients. After 2 years of EECP therapy,70% of patients reported the significant decrease in angina and nitroglycerine consumption. Arora et al. [42] performed a study on 30 patients with stable angina pectoris having class II-IV. This study was done to assess the effect of EECP on vascular cell release of coagulation factors. The author reveals that EECP may not play a significant role in controlling coagulation factors in CHD patients.
McCullough et al. [43] carried out a study on 2730 obese heart patients to evaluate the association of baseline body mass index (BMI) on the outcomes of enhanced external counterpulsation (EECP) therapy for chronic stable angina. A greater reduction in weekly angina episodes from baseline to follow up observed and study conclude that reduction of angina is directly proportional to BMI value. Akhtar et al. [44] conducted a study on 13 CHD patients to evaluate the effect of EECP treatment on plasma nitric oxide and endothelin-1 level. This study concludes that EECP may increase nitric oxide and decreases endothelin-1 levels. Soran et al. [45] carried out a cohort study on 363 CHD patients and post EECP treatment, there was a significant decrease in severity of angina class (p < 0.001), and 72% patients were improved from severe angina and 52% of patients discontinued nitroglycerin use. At 2 years of follow up 55%, patients showed improvement in angina and prove that EECP is effective and durable therapy approach for CAD patients and 52% CHD patients discontinued nitroglycerin use. Nichols et al. [46] performed a study on 20 angina patients to prove the hypothesis of arterial properties and wave reflection characteristics favourably altered after EECP. The study revealed that EECP treatment may reduce arterial stiffness and can improve wave reflection characteristics in patients with angina. 
EFFECT OF EECP ON HR-QoL IN CORONARY HEART DIsEAsE PATIENTs
arora et al. [65] conducted a study to assess EECP effectiveness on HRQoL. A significant improvement in HRQoLwas observed at 12 months of follow up. The result shows improvements in HRQoL changes after EECP treatment. Kumar et al. [66] 
did a prospective Vikram Singh et al., Effect of EECP in CHD patients
study and found that EECP significantly improved angina symptoms, dyspnea on exertion, and quality of life after 35 days of treatment and at1 year follow up. EECP also improved the 6-minute walking capacity. Wu et al. [67] performed a study to evaluate EECP after six months regarding physical capacity and HRQoL in patients with refractory AP. Patients enhanced walking distance on average by 29 m after EECP. CCS class also improved and persisted at six months follow-up. HRQoL improved significantly and the effects maintained at follow-up after the treatment. Ziaeirad et al. [68] did a quasi-experimental study on 64 patients to evaluate the QoL of patients with angina pectoris after treatment with enhanced external counterpulsation. The author reveals that EECP is an effective noninvasive method in treating patients with angina pectoris and in developing their HRQoL. Jorgensen et al. [69] conducted a special case study of the 43-year-old woman who had 15 hospital admissions in six years due to angina. The case study proves the EECP effectiveness towards angina recovery and significant improvement in HRQoL. May et al. [70] performed a study to assess the effect of EECP on QoL and exercise capacity in CAD patients. Author of this concludes that quality of life and exercise capacity was improved after eecP. shakouri et al. [71] conducted a study to investigate the effect of EECP on plasma nitric oxide (NO) and HRQoL in CAD patients. The author revealed that HRQoLand NO level increased after EECP treatment in CHD patients.Summary of studies given in Tables 3, 4 . Enhanced peripheral endothelial function immediately after EECP treatment with a contribution to the clinical benefit of EECP schecter et al. [28] 2003 External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris 20 Significant improvement in angina class (p < 0.001), nitrate consumption decrease (p < 0.001) with improvement in endothelial functions
Tartaglia et al. [29] 2003 Exercise capability and myocardial perfusion in chronic angina patients treated with enhanced external counterpulsation 25 96% patients improved by at least one functional angina class and exercise duration increased in treadmill exercise testing and reduction in ischemic segments
Werner et al. [30] 2003 Practicability and limitations of enhanced external counterpulsation as an additional treatment for angina 48 Anginal episode reduced by 48%, Nitroglycerine reduction by 51% and work capacity increase by 22% Lawson et al. [36] 2004 The effectiveness of enhanced external counterpulsation in patients with left main disease and angina.
2861
Significant improvement in angina pectoris and reduction in nitroglycerine use and reduction in weekly angina episodes observed Masuda et al. [37] 2004 Improvement of oxygen metabolism in ischemic myocardium as a result of enhanced external counterpulsation with heparin pretreatment for patients with stable angina 18 Significant improvement in exercise capacity and oxygen metabolism of CHD patients treated with EECP and intravenous heparin infusion combined therapy was observed
Henrikson et al. [38] 2004 Enhanced external counterpulsation therapy: significant clinical improvement without electrophysiologic remodelling 28 Significant improvement in angina by 82% and effective treatment for CAD patients
Taguchi et al. [39] 2004 Effects of enhanced external counterpulsation on hemodynamics and its mechanism relation to neurohumoral factors
24
Study concludes that increments in ANP without enhancement in BNP was an important mechanism for EECP effectiveness
Lawson et al. [40] 2005 Predictors of benefit in angina patients one year after completing enhanced external counterpulsation: initial responders to treatment versus non responders 2,007 Angina reduced by at least 83% immediately, and improvement in weekly anginal episodes, the frequency of nitroglycerine use decreased and well-being status improved by 63% Michaels et al. [51] 2007 The effects of enhanced external counterpulsation on time-and frequency-domain measures of heart rate variability 27 Improvement in heart rate variability in diabetic CHD patients and associated with reduced with reduced mortality rate 
Discussion
Above discussed EECP studies validates the significant improvement in CCS and NYHA angina classification, angina episodes, left ventricle ejection fraction functioning, exercise tolerance and HRQoL with reduction of nitroglycerine use & decrease hospitalization rate in coronary heart disease patients. EECP used for angina and heart failure for the past two decades, but still, more research required filling the gaps in research. There are very few or rare study conducted to assess EECP effectiveness on BMI, Heart Rate, Cholesterol, Triglyceride, High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), HbA1C, SpO 2 , Vo2max, 12-minute walk or run test and comparative prospective randomized trials on cardiac and non-cardiac metabolic markers.
Conclusion
Further clinical research is required to evaluate EECP effectiveness on obese, diabetic, hypertension and other metabolic disease patients with CHD and multi-centric randomized controlled trials are required for further modifications in EECP device to cure, prevent, and treat chronic diseases such as obesity, hypertension, diabetes, and neurological disorders by the non-invasive procedure.
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